Hôpital Privé des Cotes d'Armor
Welcome,         Profile    Billing    Logout  
 1 Trial 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MARTIN-BABAU, Jérôme
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting
2
70
Europe
Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
09/25
12/26
TUC-TOC, NCT05955170: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Recruiting
2
66
Europe
Tucatinib in Combination of Oral VP16 and trastuzumab
Institut Curie, Seagen Inc.
HER2-positive Breast Cancer
12/26
12/27
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Recruiting
2
162
Europe
Alpelisib, Fulvestrant, Ribociclib
UNICANCER, Novartis, Breast Cancer Research Foundation
Breast Cancer Stage IV
07/28
06/30
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Not yet recruiting
2
354
NA
Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol
UNICANCER, MSD France, Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris
Triple-negative Breast Cancer
12/31
12/31
ALTERNATIVE, NCT06505018: Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Recruiting
N/A
472
Europe
Cureety techcare
UNICANCER, Cureety
Metastatic Triple-Negative Breast Carcinoma
05/26
09/27
Laclautre, Lise
CADOR, NCT06444919: Capsaicin in Digital Osteoarthritis Versus Control

Not yet recruiting
4
120
Europe
Capsaicin 179 Mg Cutaneous Patch, QUTENZA, Capsaicine low dose 0.04 %, control treatment
University Hospital, Clermont-Ferrand, Grünenthal GmbH
Osteoarthritis Hand, Neuropathic Pain
01/28
01/28
RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

Completed
N/A
307
Europe
Optical Coherence Tomography (OCT)
University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT
In-stent Restenosis
12/22
12/22
DiaWorkHFNC, NCT06249009: Diaphragmatic Work During HFNC and CPAP Support

Recruiting
N/A
80
Europe
Non invasive ventilation
University Hospital, Clermont-Ferrand, Maquet Critical Care AB, Fisher and Paykel Healthcare
Respiratory Insufficiency in Children, Newborn Rds, Nasal Cannula, CPAP Ventilation
11/25
11/25
EVIGE, NCT05422157: Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System

Completed
N/A
71
Europe
University Hospital, Clermont-Ferrand, Diagnostica Stago
Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient, Patient With FV Leiden Mutation, Patient With Cirrhosis, Patient on Anticoagulant
11/23
11/23

Download Options